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inTRODUCTiOn
Lymphadenopathy (LD) is a common clinical presentation in outpatient departments (1–3). It is a 
cause of concern for the patient and physician alike even in the absence of symptoms (4). In India 
and some other developing countries, tuberculosis (TB) is the first differential diagnosis for a patient 
who presents with chronic lymph node enlargement (4–6). Nonetheless, studies have shown that 
more than 50% of cases of LD are due to non-TB causes and, in these cases, excision biopsy (EB) 
with histopathology and/or microbiological examination, is the only way to exclude TB (2, 5, 7). 
Malignancies may account for about 1% of cases of LD (1). The causes of LD can be broadly classified 
as shown below (8–10):
 1. Malignancy: lymphoma, acute lymphoblastic leukemia, acute promyelocytic leukemia, and 
metastasis.
 2. Infection: TB, streptococcal infection, pediculosis, measles, chickenpox, infectious mononucleo-
sis, HIV, toxoplasmosis, and Taenia.
 3. Autoimmune: systemic lupus erythematosus, serum sickness, juvenile idiopathic arthritis, and 
rheumatoid arthritis.
 4. Drugs: phenytoin, cotrimoxazole, allopurinol, atenolol, penicillins, etc.
 5. Miscellaneous: sarcoidosis, storage disorders, histiocytosis, cystic fibrosis, and hypothyroidism.
Of the various causes in adults, lymphoma and HIV infection should be ruled out in inconclusive 
cases (5). A retrospective analysis of 5 months data from a South African Lymphoma Clinic showed 
that out of 21 patients of lymphoma, 18 were mistakenly diagnosed as TB in the 12 months preceding 
the histological confirmation of lymphoma (11). Of the different types of lymphomas, the most 
common is “diffuse large B cell lymphoma” followed by “follicular lymphoma” (FL) (12, 13). FL is 
the most common indolent lymphoma (14). An early diagnosis of FL has become important in the 
light of availability of treatment options that can delay disease progression. LD due to FL and TB has 
a lot of similarities and differences. The article describes them with the objective of creating more 
awareness about FL enabling its early diagnosis. The presenting symptoms of FL are subtle, if any, and 
hence can be missed easily until disease progression to a more aggressive form (15–17).
LYMpHADEnOpATHY: TB AnD FL – SiMiLARiTiES (14, 18)
 1. Classically, TB LD has been described as multiple, matted, hard to fluctuant with draining sinuses. 
But in stages 1 and 2, lymph nodes may be discrete, firm, and rubbery just like FL LD (19).
FiGURE 1 | Diagnostic algorithm in a case of chronic lymphadenopathy. FNAC, fine needle aspiration cytology; AFB, acid fast bacilli; “−”, negative; “+”, 
positive; LN, lymph node. *Chronic lymphadenopathy: lymphadenopathy due to unexplained causes and duration ≥2 weeks. †Clinical suspicion of tuberculosis (TB) 
would be based on (1) past history of TB or exposure to a case of TB; (2) age <50 years; (3) typical features of TB lymph node – multiple, matted, hard to fluctuant 
with draining sinuses; (4) symptoms like – fatigue, low grade fever, night sweats, weight loss, etc. ‡Based on studies conducted on response to treatment in cases 
of TB lymphadenopathy (23–25).
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 2. Commonly involved lymph node regions in both (2, 7, 16, 17, 
20, 21): cervical, axillary, and inguinal lymph nodes.
 3. Both may have a non-specific presentation (9): fatigue, low 
grade fever, night sweats, weight loss, etc.
 4. Fine needle aspiration cytology (FNAC): both TB and FL LD 
may show evidence of granulomatous inflammation (5).
LYMpHADEnOpATHY: CLUES inDiCATinG 
nOn-TB ETiOLOGY (14, 17, 18, 20, 22)
 1. Age more than 40–50 years, since most cases of TB LD occur 
in 20–40 years age group.
 2. Supraclavicular LD may point toward a malignancy (8).
 3. No history of exposure to a case of TB.
 4. An inconclusive repeat FNAC.
 5. Normal tuberculin skin test (TST).
 6. Lack of resolution of clinical symptoms and regression of 
LD after starting anti-TB therapy (ATT). In most cases of 
non-resistant TB LD, lymph node regression occurs within 
2–4 months of start of ATT (23–25). Lack of response after 
2 months of starting therapy should lead to consideration of 
resistance or non-TB causes.
A general diagnostic algorithm in a case of chronic LD is 
presented in Figure 1.
CHROniC LD: SUGGESTED iniTiAL 
WORKUp
1. Complete blood counts, erythrocyte sedimentation rate, and a 
careful evaluation of the peripheral blood smear. (5, 15, 22, 26).
 2. Tests such as serum lactate dehydrogenase, uric acid, and 
beta-2-microglobulin are good indicators of a lymphomatous 
process.
 3. TST.
 4. A chest x-ray may indicate mediastinal enlargement in case of 
FL or lesions of pulmonary TB.
 5. Abdominal USG is an important non-invasive investigation 
in suspicious cases, since 50% of FL patients may have sple-
nomegaly (26). Especially, if splenomegaly is massive, some of 
the differential diagnosis are chronic lymphocytic leukemia, 
non-Hodgkin lymphoma, chronic myelocytic leukemia, 
polycythemia vera, myelofibrosis with myeloid metaplasia, or 
hairy cell leukemia (27, 28). Splenic involvement in TB usually 
occurs in the military form and is very rare (29, 30).
Lymph node aspirate/biopsy for microscopy/histopathology 
and culture. Atypical lymphoid hyperplasia should be considered 
non-diagnostic rather than negative for a malignancy. Careful 
follow-up and an additional lymph node biopsy must be strongly 
considered in such cases (31). Fine needle aspiration (FNA) is an 
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established investigation in the diagnosis of tuberculous lymphad-
enitis as it is a simple and relatively painless procedure (32–35). 
EB provides more information about histological architecture 
but requires surgical and anesthetic facilities and may leave a 
scar. The sensitivity of FNA and EB must be looked at in context 
of the combination diagnostic modality used. For example, for 
diagnosis of TB LAD, the sensitivity (95% CI) of FNA + cytologi-
cal assessment is 38.5% (20–59%), FNA + microscopy for acid 
fast bacilli (AFB) is 18.2% (5–40%), and FNA + culture is 86.4% 
(65–97%), whereas that for EB + histological assessment is 95.8% 
(88–100%) and EB + microscopy for AFB is 16.7% (2–32%) (33). 
A study conducted by Singh et al. showed that EB was about twice 
as sensitive as FNA examination (p < 0.05) using the conventional 
diagnostic criteria of histology and culture for TB LAD (36). The 
same study also showed that, the positivity of polymerase chain 
reaction (PCR) in TB LAD cases using material from FNA and 
EB was same (10 out 22 cases of TB LAD) but by increasing the 
quantity of the clinical specimen for PCR analyses, more number 
of cases were diagnosed by EB (15/22) compared to FNA (12/22) 
(36). Thus, PCR on FNA samples can be performed as an initial 
test and EB histology and PCR should be recommended in 
cases negative on FNA +  PCR, or if there is clinical suspicion 
for non-TB cases (36–38). For diagnosing lymphoma, although 
EB is an accepted “gold standard,” a core needle biopsy is also a 
viable alternative, provided that the number and size of cores for 
morphologic analysis are not compromised (39). GeneXpert test 
of lymph node biopsy material (40–42). It is a semiautomated and 
rapid method based on the detection of DNA of Mycobacterium 
tuberculosis and mutations responsible for rifampicin resistance 
(43). This method has been endorsed by the World Health 
Organization for rapid diagnosis of TB (44). Its utility is known 
for diagnosis of both pulmonary and extrapulmonary TB. 
According to a systematic review by Smith et al., GeneXpert test 
is likely to be of greatest utility when testing lymph node or tis-
sue samples (besides CSF), and differentiating tuberculous from 
non-tuberculous mycobacteria in smear positive samples (43). A 
study has reported that the GeneXpert test reduced the time to 
begin ATT by 4 weeks in both pulmonary and extrapulmonary 
TB cases with a negative sputum AFB smear (45). The positive 
and negative predictive values of this test are 90–100 and 70–85%, 
respectively, since it has a specificity of almost 98–100% (42, 
46–48). A negative test may not necessarily rule out TB but a 
positive test indicates TB; and hence, it has been described as 
a “rule-in” test. There are concerns about affordability but costs 
are being brought down followed by increased demand, support 
from health authorities, and public–private partnership (49, 50).
COnCLUSiOn
Though FL is one of the less common causes of LD, there should 
be a high index of suspicion in selected cases to enable an early 
diagnosis. Key factors that would point toward a non-TB cause of 
LD are age >40 years, no history of TB, normal TST, inconclusive 
FNAC, negative GeneXpert test, and non-resolution of clinical 
symptoms and/or regression of LD in 2–4 months after starting 
ATT. An early diagnosis could permit the use of drugs, which 
have been shown to delay progression of FL.
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